Drug
Fulranumab 1 mg
Fulranumab 1 mg is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
4
100%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 34 (100.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003
NCT02289716
completedphase_3
Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001
NCT02336685
completedphase_3
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002
NCT02336698
completedphase_3
Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007
NCT02301234
Clinical Trials (4)
Showing 4 of 4 trials
NCT02289716Phase 3
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003
NCT02336685Phase 3
Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001
NCT02336698Phase 3
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002
NCT02301234Phase 3
Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4